News articles about Agenus (NASDAQ:AGEN) have trended somewhat positive on Tuesday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agenus earned a news impact score of 0.22 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.009602318937 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

AGEN has been the topic of a number of recent analyst reports. ValuEngine lowered shares of Agenus from a “sell” rating to a “strong sell” rating in a report on Saturday, July 8th. Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Wednesday, July 5th. Maxim Group restated a “buy” rating and set a $7.00 price target on shares of Agenus in a report on Sunday, April 23rd. BidaskClub upgraded shares of Agenus from a “hold” rating to a “buy” rating in a report on Monday, July 24th. Finally, Jefferies Group LLC restated a “buy” rating and set a $7.00 price target on shares of Agenus in a report on Friday. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Agenus currently has a consensus rating of “Hold” and a consensus target price of $5.88.

Agenus (NASDAQ:AGEN) opened at 3.79 on Tuesday. The firm has a 50-day moving average of $4.26 and a 200 day moving average of $3.90. The firm’s market cap is $375.66 million. Agenus has a 1-year low of $3.20 and a 1-year high of $7.49.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.04. Agenus had a negative net margin of 280.96% and a negative return on equity of 37,577.49%. The firm had revenue of $4.21 million for the quarter, compared to analyst estimates of $6.66 million. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. The business’s revenue was down 36.1% on a year-over-year basis. Analysts expect that Agenus will post ($1.17) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Agenus (AGEN) Earning Somewhat Positive Press Coverage, Report Finds” was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Insider Buying and Selling by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with's FREE daily email newsletter.